Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 11:45 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 7,408 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Tissue specimen Clear all
Recruiting Not applicable Interventional

CMN LIFU for Enhanced Amyloid Reduction (CLEART Study)

NCT07866768
View directory record Official record
Conditions
Alzheimer's Disease (AD), Mild Cognitive Impairment (MCI), Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease
Interventions
ATTN201 Focused Ultrasound to the CMN, ATTN201 Unfocused Ultrasound
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
65 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 9, 2026 · Synced Nov 11, 2026, 11:45 AM EST
Completed No phase listed Observational

Identifying Cancer Genes in in Blood and Bone Marrow Samples From Patients With Acute Myeloid Leukemia

NCT00897182
View directory record Official record
Conditions
Leukemia
Interventions
microarray analysis, polymerase chain reaction
Genetic
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Not listed
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
2
States / cities
Fort Wayne, Indiana • Goldsboro, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 4, 2016 · Synced Nov 11, 2026, 11:45 AM EST
Terminated Phase 1 Interventional

Elastographic Imaging of Renal Transplants

NCT00935727
View directory record Official record
Conditions
Renal Transplant
Interventions
Elastographic imaging
Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2009 · Synced Nov 11, 2026, 11:45 AM EST
Not listed Phase 1 Interventional Accepts healthy volunteers

Preventing Preterm Birth With a Negative Pressure Cervical Cup: a Feasibility Study

NCT05512052
View directory record Official record
Conditions
Preterm Birth, Cervical Incompetence, Cervical Insufficiency, Short Cervix, Soft Cervix
Interventions
Hannah Cervical Cup (2 mm Delta), Hannah Cervical Cup (4 mm Delta), Hannah Cervical Cup (6 mm Delta)
Device
Lead sponsor
Galena Innovations, LLC
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Provo, Utah
Source: ClinicalTrials.gov public record
Updated Aug 26, 2022 · Synced Nov 11, 2026, 11:45 AM EST
Completed Not applicable Interventional

How Safe and Effective is Micropulse Transscleral Cyclophotocoagulation in Patients With Uncontrolled Glaucoma?

NCT02627352
View directory record Official record
Conditions
Glaucoma
Interventions
Micropulse Transscleral Cyclophotocoagulation
Procedure
Lead sponsor
Wills Eye
Other
Eligibility
20 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 11, 2017 · Synced Nov 11, 2026, 11:45 AM EST
Completed Not applicable Interventional

Study of Artelon FLEXBAND® for Patients Undergoing Soft Tissue Reconstruction of the Anterior Talofibular Ligament (ATFL) to Treat Lateral Ankle Instability

NCT06638138
View directory record Official record
Conditions
Lateral Ankle Instability
Interventions
Flexband
Device
Lead sponsor
Stryker Trauma and Extremities
Industry
Eligibility
18 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
8
States / cities
Phoenix, Arizona • Gainesville, Florida • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Nov 11, 2026, 11:45 AM EST
Completed Phase 3 Interventional Results available

Tenecteplase in Stroke Patients Between 4.5 and 24 Hours

NCT03785678
View directory record Official record
Conditions
THROMBOLYSIS
Interventions
Tenecteplase, Placebo
Biological · Other
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
94
States / cities
Birmingham, Alabama • Mesa, Arizona • Anaheim, California + 74 more
Source: ClinicalTrials.gov public record
Updated May 22, 2024 · Synced Nov 11, 2026, 11:45 AM EST
Not listed Not applicable Interventional

Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects

NCT02090140
View directory record Official record
Conditions
Degenerative Lesion of Articular Cartilage of Knee
Interventions
ADSC Application, Microfracture
Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 50 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
3
States / cities
Redwood City, California • Santa Monica, California • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Nov 11, 2026, 11:45 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Effects of Tirzepatide on Blood, Imaging and Breast Tissue Biomarkers

NCT06485089
View directory record Official record
Conditions
Obesity, Breast Cancer Risk
Interventions
tirzepatide
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
40 Years to 64 Years · Female only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
2
States / cities
Kansas City, Kansas • Westwood, Kansas
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Nov 11, 2026, 11:45 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

ivWatch Model 400: Device Validation for Non-Infiltrated Tissues

NCT02120443
View directory record Official record
Conditions
Infiltration of Peripheral IV Therapy
Interventions
ivWatch Model 400
Device
Lead sponsor
ivWatch, LLC
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Williamsburg, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 2, 2014 · Synced Nov 11, 2026, 11:45 AM EST
Recruiting Phase 1 Interventional

MTI-301 for the Treatment of Metastatic or Unresectable and Refractory Solid Cancers

NCT06911008
View directory record Official record
Conditions
Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, SCD1 Inhibitor MTI-301
Procedure · Other · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Nov 11, 2026, 11:45 AM EST
Completed Phase 2 Interventional Results available

Erlotinib in Treating Patients With Breast Cancer That Can Be Removed by Surgery

NCT00633750
View directory record Official record
Conditions
Breast Cancer
Interventions
erlotinib hydrochloride, TUNEL assay, protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, liquid chromatography, mass spectrometry, matrix-assisted laser desorption ionization mass spectrometry, therapeutic conventional surgery
Drug · Genetic · Other + 1 more
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
5
States / cities
Birmingham, Alabama • Boston, Massachusetts • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2012 · Synced Nov 11, 2026, 11:45 AM EST
Completed Phase 1 Interventional

A Phase 1b Study to Assess the Safety and Anti-inflammatory Effects of Two Different Doses of SRT2104 in Patients With Ulcerative Colitis

NCT01453491
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
SRT2104
Drug
Lead sponsor
Sirtris, a GSK Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
13
States / cities
Anaheim, California • Bristol, Connecticut • Owensboro, Kentucky + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Nov 11, 2026, 11:45 AM EST
Active, not recruiting Phase 1 Interventional

Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

NCT03170960
View directory record Official record
Conditions
Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Castration-resistant Prostate Cancer, Triple Negative Breast Cancer, Ovarian Cancer, Endometrial Cancer, Hepatocellular Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Colorectal Cancer, Head and Neck Cancer, Differentiated Thyroid Cancer, Lower Esophageal Cancer
Interventions
cabozantinib, atezolizumab
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
914 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
57
States / cities
Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 45 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Nov 11, 2026, 11:45 AM EST
Not listed Phase 3 Interventional

Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19

NCT04334382
View directory record Official record
Conditions
COVID-19
Interventions
Hydroxychloroquine, Azithromycin
Drug
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
45 Years and older
Enrollment
1,550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Murray, Utah • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 9, 2020 · Synced Nov 11, 2026, 11:45 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Uterine Leiomyoma Treatment With Radiofrequency Ablation

NCT01840124
View directory record Official record
Conditions
Uterine Fibroids
Interventions
Radiofrequency ablation of fibroids
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years and older · Female only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2020
U.S. locations
5
States / cities
Davis, California • Irvine, California • La Jolla, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Nov 11, 2026, 11:45 AM EST
Completed Not applicable Interventional

Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer

NCT00296023
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
anti-thymocyte globulin, filgrastim, therapeutic allogeneic lymphocytes, busulfan, fludarabine phosphate, methotrexate, tacrolimus, nonmyeloablative allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
2
States / cities
Berkeley, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 4, 2012 · Synced Nov 11, 2026, 11:45 AM EST
Terminated Phase 4 Interventional

Cosmetic Outcome Study of Lid Laceration Repair With Suture Versus Tissue Adhesive

NCT01918059
View directory record Official record
Conditions
Eyelid Laceration
Interventions
Tissue Adhesive skin closure, Absorbable suture skin closure, Non-absorbable suture skin closure
Procedure
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 3, 2014 · Synced Nov 11, 2026, 11:45 AM EST
Terminated Phase 2 Interventional Results available

Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other Disease

NCT00392782
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
anti-thymocyte globulin, fludarabine phosphate, thiotepa, peripheral blood stem cell transplantation, total-body irradiation
Biological · Drug · Procedure + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 60 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
9
States / cities
Tampa, Florida • Atlanta, Georgia • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Nov 11, 2026, 11:45 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Bioactive Split Thickness Skin Allograft Versus Standard of Care in the Treatment of Diabetic Foot Ulcers

NCT04040426
View directory record Official record
Conditions
Diabetic Foot, Ulcer Foot
Interventions
Human split thickness skin allograft, Additional Outer Dressing Applicaiton, Offloading, Fibracol Wound Dressing
Other
Lead sponsor
Professional Education and Research Institute
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
5
States / cities
San Francisco, California • O'Fallon, Illinois • Youngstown, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2022 · Synced Nov 11, 2026, 11:45 AM EST
Completed Phase 1 Interventional

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Followed by Surgery and/or Radiation Therapy in Treating Young Patients With Advanced Neuroblastoma

NCT00002740
View directory record Official record
Conditions
Neuroblastoma
Interventions
filgrastim, carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, mesna, vincristine sulfate, conventional surgery, peripheral blood stem cell transplantation, low-LET cobalt-60 gamma ray therapy, low-LET photon therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2005
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Nov 11, 2026, 11:45 AM EST
Terminated No phase listed Observational Accepts healthy volunteers

Establishment of a Tissue Bank (Blood, CSF) for the Understanding of Motor Neuron Disease (MND)

NCT01950910
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
766 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2020
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 11, 2022 · Synced Nov 11, 2026, 11:45 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Levels of Raltegravir in the Female Genital Tissue

NCT01327482
View directory record Official record
Conditions
HIV
Interventions
Raltegravir
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 19, 2014 · Synced Nov 11, 2026, 11:45 AM EST
Active, not recruiting Phase 2 Interventional

Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus

NCT05966480
View directory record Official record
Conditions
SLE
Interventions
Envudeucitinib, Placebo
Drug
Lead sponsor
Alumis Inc
Industry
Eligibility
18 Years to 70 Years
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
48
States / cities
Anniston, Alabama • La Jolla, California • Los Alamitos, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Nov 11, 2026, 11:45 AM EST